{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:28:26Z","timestamp":1774438106452,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,6,16]],"date-time":"2016-06-16T00:00:00Z","timestamp":1466035200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s13300-016-0174-y","type":"journal-article","created":{"date-parts":[[2016,6,16]],"date-time":"2016-06-16T10:07:43Z","timestamp":1466071663000},"page":"455-471","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Population Pharmacokinetics and Exposure\u2013Response (Efficacy and Safety\/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes"],"prefix":"10.1007","volume":"7","author":[{"given":"Kyle T.","family":"Baron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreeraj","family":"Macha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uli C.","family":"Broedl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Nock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Retlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Riggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,16]]},"reference":[{"issue":"374","key":"174_CR1","first-page":"e9","volume":"123","author":"RM Bergenstal","year":"2010","unstructured":"Bergenstal RM, Bailey CJ, Kendall DM. Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications. Am J Med. 2010;123(374):e9\u201318.","journal-title":"Am J Med"},{"key":"174_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2165\/11587580-000000000-00000","volume":"11","author":"AV Hernandez","year":"2011","unstructured":"Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazoldinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs. 2011;11:115\u201328.","journal-title":"Am J Cardiovasc Drugs."},{"key":"174_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.tips.2010.11.011","volume":"32","author":"CJ Bailey","year":"2011","unstructured":"Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci. 2011;32:63\u201371.","journal-title":"Trends Pharmacol Sci"},{"key":"174_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1210\/jc.2009-0473","volume":"95","author":"S Nair","year":"2010","unstructured":"Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab. 2010;95:34\u201342.","journal-title":"J Clin Endocrinol Metab"},{"key":"174_CR5","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1093\/ndt\/gfl175","volume":"21","author":"K Rave","year":"2006","unstructured":"Rave K, Nosek L, Posner J, Heise T, Roggen K, van Hoogdalem EJ. Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes\u2014results of a hyperglycaemic glucose clamp study. Nephrol Dial Transplant. 2006;21:2166\u201371.","journal-title":"Nephrol Dial Transplant"},{"key":"174_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0168-8227(97)01389-2","volume":"36","author":"B Ruhnau","year":"1997","unstructured":"Ruhnau B, Faber OK, Borch-Johnsen K, Thorsteinsson B. Renal threshold for glucose in non-insulin-dependent diabetic patients. Diabetes Res Clin Pract. 1997;36:27\u201333.","journal-title":"Diabetes Res Clin Pract"},{"key":"174_CR7","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/dom.12073","volume":"15","author":"T Heise","year":"2013","unstructured":"Heise T, Seewaldt-Becker E, Macha S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4\u00a0weeks\u2019 treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15:613\u201321.","journal-title":"Diabetes Obes Metab"},{"key":"174_CR8","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/dom.12081","volume":"15","author":"E Ferrannini","year":"2013","unstructured":"Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15:721\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"174_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/cpdd.16","volume":"2","author":"L Seman","year":"2013","unstructured":"Seman L, Macha S, Nehmiz G, et al. Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharm Drug Dev. 2013;2:152\u201361.","journal-title":"Clin Pharm Drug Dev."},{"key":"174_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2133\/dmpk.DMPK-12-RG-082","volume":"28","author":"A Sarashina","year":"2013","unstructured":"Sarashina A, Koiwai K, Seman LJ, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet. 2013;28:213\u20139.","journal-title":"Drug Metab Pharmacokinet"},{"key":"174_CR11","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/jdi.12110","volume":"4","author":"S Kanada","year":"2013","unstructured":"Kanada S, Koiwai K, Taniguchi A, Sarashina A, Seman L, Woerle HJ. Pharmacokinetics, pharmacodynamics, safety and tolerability of 4\u00a0weeks\u2019 treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Invest. 2013;4:613\u20137.","journal-title":"J Diabetes Invest."},{"key":"174_CR12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s13300-013-0030-2","volume":"4","author":"T Heise","year":"2013","unstructured":"Heise T, Seman L, Macha S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Ther. 2013;4:331\u201345.","journal-title":"Diabetes Ther."},{"key":"174_CR13","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","volume":"1","author":"M Roden","year":"2013","unstructured":"Roden M, Weng J, Elibracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1:208\u201319.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"174_CR14","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.2337\/dc13-2105","volume":"37","author":"HU H\u00e4ring","year":"2014","unstructured":"H\u00e4ring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37:1650\u20139.","journal-title":"Diabetes Care"},{"key":"174_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/dom.12188","volume":"16","author":"CS Kovacs","year":"2014","unstructured":"Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2014;16:147\u201358.","journal-title":"Diabetes Obes Metab"},{"key":"174_CR16","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.2337\/dc13-3055","volume":"37","author":"J Rosenstock","year":"2014","unstructured":"Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37:1815\u201323.","journal-title":"Diabetes Care"},{"key":"174_CR17","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/dom.12185","volume":"15","author":"J Rosenstock","year":"2013","unstructured":"Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab. 2013;15:1154\u201360.","journal-title":"Diabetes Obes Metab"},{"key":"174_CR18","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1111\/bcp.12453","volume":"78","author":"MM Riggs","year":"2014","unstructured":"Riggs MM, Seman LJ, Staab A, et al. Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes. Br J Clin Pharmacol. 2014;78:1407\u201318.","journal-title":"Br J Clin Pharmacol"},{"key":"174_CR19","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/jcph.147","volume":"53","author":"MM Riggs","year":"2013","unstructured":"Riggs MM, Staab A, Seman L, et al. Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes. J Clin Pharmacol. 2013;53:1028\u201338.","journal-title":"J Clin Pharmacol"},{"key":"174_CR20","volume-title":"Model selection and multimodel inference: a practical information-theoretic approach","author":"KP Burnham","year":"2002","unstructured":"Burnham KP, Anderson DR. Model selection and multimodel inference: a practical information-theoretic approach. New York: Springer-Verlag; 2002."},{"key":"174_CR21","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/bdd.700","volume":"31","author":"MN Samtani","year":"2010","unstructured":"Samtani MN. Simple pharmacometric tools for oral anti-diabetic drug development: competitive landscape for oral non-insulin therapies in type 2 diabetes. Biopharm Drug Dispos. 2010;31:162\u201377.","journal-title":"Biopharm Drug Dispos"},{"key":"174_CR22","unstructured":"Gastonguay MR. Full covariate models as an alternative to methods relying on statistical significance for inferences about covariate effects: a review of methodology and 42 case studies. 2011. http:\/\/www.page-meeting.org\/default.asp?abstract=2229#. Accessed 28 Apr 2016."},{"key":"174_CR23","unstructured":"R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing;2008."},{"key":"174_CR24","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.2337\/dc13-0663","volume":"36","author":"E Ferrannini","year":"2013","unstructured":"Ferrannini E, Berk A, Hantel S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care. 2013;36:4015\u201321.","journal-title":"Diabetes Care"},{"key":"174_CR25","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.clinthera.2014.08.001","volume":"36","author":"A Sarashina","year":"2014","unstructured":"Sarashina A, Ueki K, Sasaki T, et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus. Clin Ther. 2014;36:1606\u201315.","journal-title":"Clin Ther"},{"key":"174_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/dom.12182","volume":"16","author":"S Macha","year":"2014","unstructured":"Macha S, Mattheus M, Halabi A, Pinnetti S, Woerle HJ, Broedl UC. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab. 2014;16:215\u201322.","journal-title":"Diabetes Obes Metab"},{"key":"174_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","volume":"75","author":"AJ Scheen","year":"2015","unstructured":"Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75:33\u201359.","journal-title":"Drugs."},{"key":"174_CR28","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","volume":"2","author":"AH Barnett","year":"2014","unstructured":"Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:369\u201384.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"174_CR29","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499\u2013508.","journal-title":"J Clin Invest."}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-016-0174-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13300-016-0174-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-016-0174-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T17:38:36Z","timestamp":1718645916000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13300-016-0174-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,16]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["174"],"URL":"https:\/\/doi.org\/10.1007\/s13300-016-0174-y","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,16]]},"assertion":[{"value":"15 February 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2016","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}